Search Results
Your search for ,OUr matches 10724 pages
Showing 4051 - 4100Rates of Testicular Cancer Rising Among Racial/Ethnic Minorities in the United States
Between 2001 and 2016 in the United States, Asian/Pacific Islander men experienced the greatest increase in the incidence of testicular germ cell tumors, followed by Hispanic and American Indian/Alaska Native men, according to a study published by Ghazarian et al in Cancer Epidemiology, Biomarkers...
Phyllis F. Cantor Center for Research in Nursing and Patient Care Services Awarded $1.3 Million for Cancer Projects
Nurse-scientists from the Phyllis F. Cantor Center for Research in Nursing and Patient Care Services at Dana-Farber Cancer Institute, Boston, received more than $1.3 million in funding for two separate research projects. The American Association for Cancer Research announced that in partnership...
Pamela Hull, PhD, Appointed Associate Director of Population Science and Community Impact at Kentucky Cancer Center
The University of Kentucky Markey Cancer Center announced that medical sociologist Pamela Hull, PhD, will join the center as Associate Director of Population Science and Community Impact. She will also serve as the William Stamps Farish Endowed Chair in Cancer Research and join the University of...
Impact of the COVID-19 Pandemic on Pediatric Cancer Care in Latin America
In a commentary published in The Lancet Oncology, Vasquez et al presented results of a survey of pediatric oncologists/hematologists across Latin America, which showed an adverse early impact of the COVID-19 pandemic on pediatric cancer care. Study Details The study included a cross-sectional...
Men of Color Remain Underrepresented in Prostate Cancer Clinical Trials
An analysis of 59 prostate cancer clinical trials based in North America and Europe found that the vast majority of enrollees were non-Hispanic white men, according to a study published by Rencsok et al in Cancer Epidemiology, Biomarkers & Prevention. The proportion of white participants in...
Nivolumab vs Bevacizumab in Recurrent Glioblastoma
As reported in JAMA Oncology by David A. Reardon, MD, and colleagues, the phase III CheckMate 143 trial showed no difference in overall survival among adult patients with a first recurrence of glioblastoma treated with nivolumab vs bevacizumab following standard radiation and temozolomide therapy. ...
Results From an Oncology Hospital-at-Home Evaluation
Researchers at Huntsman Cancer Institute (HCI) at the University of Utah presented the first outcomes evaluation of an adult oncology hospital-at-home program during the ASCO20 Virtual Scientific Program (Abstract 7000). The study evaluated patients participating in HCI's Huntsman at Home program....
Does Treatment With Immune Checkpoint Inhibitors Cause Flare-ups in Patients With Preexisting IBD or Microscopic Colitis?
In a retrospective analysis reported in JCO Oncology Practice, Grover et al found that enterocolitis flares occurred in approximately one-quarter of patients with preexisting inflammatory bowel disease (IBD) or microscopic colitis who received immune checkpoint inhibitors for the treatment of solid ...
A Nobel Laureate’s Road to Research Is Not Without Challenges
The 2019 Nobel Prize for Physiology and Medicine was jointly awarded to three researchers. Their discoveries paved the way for promising new strategies to treat anemia, cancer, and many other diseases. One of the three Nobel Laureates is William G. Kaelin, Jr, MD, who continues his research at his...
International Medical and Radiation Oncologist Balances Cancer Research and Clinical Practice
The Revolutions of 1989 that resulted in the end of communist rule in Central and Eastern Europe and beyond began in Poland. Perhaps if not for that social upheaval, the career of internationally renowned oncologist Jacek Jassem, MD, PhD, would have taken a very different path. Dr. Jassem had fled...
An Early Interest in Cancer Immunology Inspires a Life’s Work in Melanoma
F. Stephen Hodi, MD, Director of the Melanoma Center and the Center for Immuno-Oncology at Dana-Farber/Brigham and Women’s Cancer Center, was born in Framingham and grew up in the town of Acton, a western suburb of Boston. “My dad was an engineer, and I was influenced by puzzle-solving and using...
ASCO’s President Aims to Ensure Equitable Cancer Care for Every Patient
The desire to pursue a career in medicine took root when Lori J. Pierce, MD, FASTRO, FASCO, was a young child visiting family in segregated Ahoskie, North Carolina. She witnessed firsthand the impact the town’s lone African American family physician had on the community. When it came time to...
From the United States to Germany and Back Again to Become ASCO President in 2021–2022
ASCO President-Elect Everett E. Vokes, MD, FASCO, is the John E. Ultmann Professor, Chair of the Department of Medicine, and Physician-in-Chief of University of Chicago Medicine and Biological Sciences. After a journey from the United States to Germany and back again, Dr. Vokes arrived at the...
The ASCO Post and Narratives in Oncology Through the Years
THE ASCO POST is pleased to acknowledge its 10th anniversary. Our first issue was launched in June 2010 at the ASCO Annual Meeting. Beginning in 2012, The ASCO Post introduced Narratives in Oncology, a special commemorative issue profiling leaders in the oncology community. To nominate an...
Tribute to Bernard Fisher, MD
Bernard Fisher, MD, who died on October 16, 2019, at the age of 101, is recognized today for his groundbreaking research in breast cancer, which ultimately ended the standard practice of performing the Halsted radical mastectomy, a treatment that had been in place for more than 75 years. His...
Renowned Researcher and Surgeon Helps to Transform Treatment of Breast Cancer
Although ‘paradigm shifts’ are frequently referenced in oncology, these are really few and far between. They occur when new data either partially invalidate previously accepted theory or are at complete odds with the existing paradigm. Moving away from the Halsted radical mastectomy, a standard of ...
Internationally Regarded Cancer Immunologist Did Not Stray Far From Home
Internationally recognized immune-oncology melanoma expert Jedd D. Wolchok, MD, PhD, FASCO, was born and reared in Staten Island, not far from where he would shape his noted career at Memorial Sloan Kettering Cancer Center (MSK) in New York, New York. “I went to Princeton University and, during my ...
Expert in Clinical Trial Methodology Makes His Mark in Genitourinary Cancer
In 2019, at the ASCO Annual Meeting, Ian Tannock, MD, PhD, DSc, FASCO, was honored with the Allen S. Lichter Visionary Award for his contributions to the fields of genitourinary and breast cancers as well as his efforts to optimize clinical trial design. The title of his lecture was “Clinical...
Love of Science and a Family Tragedy Set the Course for This Breast Cancer Researcher
When oncology luminary Joyce A. O’Shaughnessy, MD, was in her early teens, her youngest sister, Teri, developed acute lymphocytic leukemia at age 5. Dr. O’Shaughnessy, the oldest of four girls, recalled that her sister’s struggle with the disease had a profound effect on her worldview. “Teri went...
Early Local Therapy Did Not Extend Survival in Patients With Newly Diagnosed Metastatic Breast Cancer
Women who present at diagnosis with advanced breast cancer have faced an unanswered question: will local therapy, consisting of surgery and radiation to the tumor in the breast, prolong survival compared to the traditional treatment of systemic treatment alone? Now, data from the randomized phase...
Ivosidenib Plus Venetoclax With or Without Azacitidine for IDH1-Mutated AML
Combination therapy with the isocitrate dehydrogenase 1 (IDH1) inhibitor ivosenidib plus the BCL2 inhibitor venetoclax with or without the chemotherapeutic agent azacitidine showed activity in patients with IDH1-mutated acute myeloid leukemia (AML) in a phase Ib/II trial. The results of the...
Transoral Resection Followed by Low-Dose Radiation for Some Oropharyngeal Cancers
The final results of the randomized phase II ECOG-ACRIN E3311 trial were presented by Robert L. Ferris, MD, PhD, and colleagues during the ASCO20 Virtual Scientific Program (Abstract 6500) and in today's Head and Neck Cancer Oral Abstract Session. The trial, conducted in patients undergoing...
Coagulation Issues in Patients With COVID-19: Part 2
In part 2 of our conversation with Dr. Syed Abutalib, Associate Director of the Hematology and Cellular Therapy Program and Director of the Clinical Apheresis Program at Cancer Treatment Centers of America, Zion, Illinois; Associate Professor at the Roseland Franklin University of Medicine and...
Precision Medicine Is Becoming a Reality for Pediatric Patients With Cancer
Although 84% of children with cancer survive 5 years or more, children with refractory, relapsed, and progressive high-risk malignancies have a poor median survival of 9.5 months. The German INFORM registry is a large prospective, noninterventional, multicenter study collecting clinical and...
Adjuvant Osimertinib in Early-Stage EGFR-Positive NSCLC
Adjuvant osimertinib significantly improved disease-free survival compared with placebo in patients with stage IB to IIIA EGFR-mutated non–small cell lung cancer (NSCLC) who underwent complete resection of primary tumor and received chemotherapy if indicated. These results from the first interim...
Lymphoma: Many Questions, Too Few Answers
The successful treatment of malignant lymphoma has been one of the great achievements in medical oncology, but certainly more work is needed to define key biologic targets as well as molecular markers for a more accurate definition of prognosis following therapy. In day-to-day practice, unanswered...
ASCO as a Public Organization: No Longer Hiding Our Lamp Under a Basket
Like many professional organizations in the public sphere, ASCO regularly confronts policy issues. Because we are a large organization, and because we represent many constituencies, we are frequently called upon to offer our advice to the federal government. Our members must sometimes wonder where...
Introducing The ASCO Post
Over the years I have become increasingly proud of the American Society of Clinical Oncology. I believe that ASCO is unique among specialty societies—at least in the various disciplines of oncology and hematology. Our Society is amazingly democratic (ie, with an independent nominating process and...
Why The ASCO Post?
It has been 5 years since ASCO has been part of a new publication, the last being the Journal of Oncology Practice (JOP). As the ASCO Board and leadership evaluated the publication mix we recognized there was a gap that needed to be filled. The Journal of Clinical Oncology (JCO), now 25 years old, ...
Expert Point of View: Axel Grothey, MD
Sharing his perspective on KEYNOTE-177 with The ASCO Post was Axel Grothey, MD, Director of GI Cancer Research at the West Cancer Center, OneOncology, Memphis. “This is a very important, highly anticipated study,” he said. “It’s the first randomized trial of any checkpoint inhibitor in...
Sources for Better GVHD-Free Relapse-Free Survival After Adult Alternative Donor HCT
In a retrospective study of registry data reported in the Journal of Clinical Oncology, Mehta et al identified alternative donor sources for hematopoietic cell transplantation (HCT) that were associated with better graft-vs-host disease (GVHD)-free (GRFS) and chronic GVHD–free (CRFS) relapse-free...
ESMO Breast 2020: Study Finds Physical Activity, Supportive Care to Relieve Cancer-Related Fatigue May Be Underutilized by Breast Cancer Survivors
Cancer-related fatigue is a prevalent and potentially persistent issue among breast cancer survivors. A study presented by Di Meglio et al at the ESMO Breast Cancer Virtual Meeting 2020 (Abstract 183O) has now shown that existing recommendations and proven strategies for reducing fatigue—which can...
ASBrS 2020: Phone Outreach and Scheduling Assistance Boost Mammography Uptake at an Urban Safety-Net Hospital
Telephone outreach coupled with scheduling assistance significantly increased screening mammography setup and follow-through in a population characterized by low rates of screening mammography and high rates of advanced breast cancer at diagnosis. These are findings from a new study conducted by...
Jennifer C. King, PhD, Named CSO of GO2 Foundation
GO2 Foundation for Lung Cancer (GO2 Foundation) has promoted Jennifer C. King, PhD, to the role of Chief Scientific Officer. In her new position, Dr. King will be responsible for leading scientific and research priorities for a global patient advocacy group dedicated to saving, extending, and...
The Arc of Therapy—From Cure to Humbling Legacy
The ASCO Post is pleased to reproduce installments of Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays, historical...
A Daughter of Immigrant Doctors, Nina Kadan-Lottick, MD, MSPH, Chose a Career in Pediatric Oncology
In 2003, Nina Kadan-Lottick, MD, MSPH, established the regional Yale HEROS multidisciplinary research and clinical program for long-term survivors of childhood cancer survivors, which is the first of its kind in Connecticut and one of the first in the United States. She intends the HEROS program to ...
COVID-19 Evidence Accelerator Leverages Real-World Data
The Reagan-Udall Foundation for the U.S. Food and Drug Administration (FDA) in collaboration with Friends of Cancer Research recently announced the COVID-19 Evidence Accelerator, an expansive public-private partnership combining the efforts of academic, government, and private sector organizations...
Researcher and Leader in Cancer Center Administration, John W. Yarbro, MD, PhD, Dies at 88
Most who leave a mark in life are noted for a single contribution; few are remembered for the breadth of their contributions. Such a man was John W. Yarbro, MD, PhD, who, near the end of his rich life, stepped foot on Antarctica, completing his desire to have visited all of the world’s seven...
The Story of Three Patients With Leukemia
The human drama within the oncology world is a never-ending story of triumph, tragedy, and all of the valiant efforts and human emotions in between. The doctor-patient relationship in oncology is deeper and longer than in most medical specialties due to the life-and-death stakes at play after a...
Ancestry and Molecular Makeup of Cancer Evaluated in New Study
A new study by researchers from the National Cancer Institute (NCI) Cancer Genome Analysis Network, a collaborative group with investigators in the United States, Canada and Europe, provides the most comprehensive look to date at the effect of ancestry on the molecular makeup of normal and...
Gynecologic Oncologist Describes His New Normal in a New York Hospital
During the COVID-19 pandemic, The ASCO Post will be interviewing oncologists on how they and their centers are dealing with the crisis. Here, we speak with Alexander Melamed, MD, MPH, a gynecologic oncologist and Assistant Professor of Obstetrics & Gynecology at NewYork-Presbyterian/Columbia...
Roswell Park Investigators Study Immunotherapy Combination in Patients With Cancer Infected With COVID-19
A clinical trial investigating a two-drug immunotherapy combination will soon be available to patients with cancer infected with COVID-19 at Roswell Park Comprehensive Cancer Center in Buffalo. The U.S. Food and Drug Administration (FDA) has authorized clinical researchers at the center to conduct...
Treating Patients With Leukemia During the COVID-19 Era at MD Anderson Cancer Center
As part of a series of interviews with cancer experts during the COVID-19 pandemic, The ASCO Post spoke with Hagop Kantarjian, MD, Professor and Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, Houston, about the impact of the pandemic on treatment of...
NIH Aims to Quantify Undetected Cases of Coronavirus Infection
A new study has begun recruiting at the National Institutes of Health (NIH) in Bethesda, Maryland, to determine how many adults in the United States without a confirmed history of infection with SARS-CoV-2, the virus that causes COVID-19, have antibodies to the virus. The presence of antibodies in...
OneOncology Names Jeff Patton, MD, Chief Executive Officer
Jeff Patton, MD, has been named Chief Executive Officer of OneOncology, a national partnership of independent community oncologists. Dr. Patton has been Acting Chief Executive Officer and President of Physician Services since February. Dr. Patton will continue as Executive Chairman of the Board of ...
Melanoma Research Alliance Announces $11 Million for Grant Awards
In recognition of Melanoma Awareness Month, the Melanoma Research Alliance has announced funding for 26 research awards, totaling $10.9 million. These grant awards are made possible through the significant contributions of individuals, families, institutions, and corporate allies. The 26 awards...
Despites Advances, Treatment-Related Sequelae Remain Problematic in Pediatric Neuro-oncology
The management of pediatric brain and spinal cord tumors is extremely complex, as are the survivorship issues in this highly vulnerable patient population. To shed light on the current clinical reality in this setting, The ASCO Post recently spoke with Katherine E. Warren, MD, an internationally...
Being Interviewed on Zoom? Here Are Some Professional Tips
You’ve agreed to be interviewed on Zoom. If you’re like most people, the technology itself isn’t a barrier. (And if it is, you can consult our step-by-step guide to using Zoom at https://bit.ly/2yxcTN0.) However, you might be less sure about what you can do to make the best impression (and the most ...
How California Dreamer John Craig Venter, PhD, Changed Paths to Focus on Sequencing the Human Genome
In this edition of the Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with John Craig Venter, PhD, Founder, Chairman, and Chief Executive Officer of the J. Craig Venter Institute, a nonprofit organization dedicated to human, microbial, and environmental genomic research. A...
How the COVID-19 Pandemic Is Propelling the Delivery of Home Care for Patients With Cancer
In 2019, the Penn Center for Cancer Care Innovation at the University of Pennsylvania’s Abramson Cancer Center began planning a demonstration program, called Cancer Care at Home, to broaden the delivery of oncology treatments to patients in the home setting. The existing services offered by Penn...
